{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:18:13Z","timestamp":1783073893893,"version":"3.54.6"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.103912","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:39:11Z","timestamp":1783071551000},"page":"103912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Less Actually More? Precision Is the Key!"],"prefix":"10.1016","volume":"21","author":[{"given":"Seng Wee","family":"Cheo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-9860","authenticated-orcid":false,"given":"Pei Jye","family":"Voon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103912_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cllc.2023.12.011","article-title":"Pembrolizumab plus chemotherapy per PD-L1 stratum in patients with metastatic non\u2013small cell lung cancer: real-world effectiveness versus trial efficacy","volume":"25","author":"Verschueren","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103912_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jtho.2024.09.052","article-title":"OA08.07 sacituzumab govitecan + pembrolizumab + carboplatin in 1L metastatic non-small cell lung cancer: The EVOKE-02 study","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103688","article-title":"Datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy for advanced or metastatic NSCLC: the phase Ib TROPION-Lung02 trial","volume":"21","author":"Levy","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.103912_bib7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the Phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib9","article-title":"118MO trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): interim analysis of a phase Ib study","volume":"24","author":"Italiano","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.jtho.2026.103912_bib10","article-title":"Trastuzumab deruxtecan in patients with HER2-overexpressing NSCLC: results from Part 1 of the open-label, multicenter, Phase 1b DESTINY-Lung03 trial","author":"Planchard","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104164","article-title":"8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohorts 2 and 4)","volume":"10","author":"Cuppens","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.103912_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.10.016","article-title":"First-line sacituzumab govitecan plus pembrolizumab in metastatic NSCLC: PD-L1 TPS less than 50% and more than or equal to 50% cohorts of the EVOKE-02 study","volume":"21","author":"Reck","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","article-title":"First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohort 5)","volume":"43","author":"Waqar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib14","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","article-title":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","volume":"31","author":"Hong","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103912_bib15","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB260","article-title":"Abstract LB260: Potential prognostic\/predictive biomarkers for sacituzumab govitecan in EVOKE-01","volume":"85","author":"Garassino","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103912_bib16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103912_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2010.05.010","article-title":"The platinum-based treatments for advanced non-small cell lung cancer, is low\/negative ERCC1 expression better than high\/positive ERCC1 expression? A meta-analysis","volume":"70","author":"Chen","year":"2010","journal-title":"Lung Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426003655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426003655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:39:51Z","timestamp":1783071591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426003655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556086426003655"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103912","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Less Actually More? Precision Is the Key!","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103688","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103912"}}